Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study

Background: Extraintestinal manifestations (EIMs) in patients with inflammatory bowel disease (IBD) are frequently observed. Little is known about the efficacy of anti–tumor necrosis factor (TNF) in EIM management. We assessed the effect of 3 anti-TNF agents (infliximab, adalimumab, and certolizumab pegol) on EIM evolution. Methods: Data on 1249 patients from the Swiss IBD Cohort Study (SIBDCS) were analyzed. All EIMs were diagnosed by relevant specialists. Response was classified into improvement, stable disease, and clinical worsening based on the physician's interpretation. Results: Of the 366 patients with at least 1 EIM, 213 (58.2%) were ever treated with an anti-TNF. A total of 299 treatments were started for 355 EIMs. Patients with EIM were significantly more often treated with anti-TNF compared with those without EIM (58.2% versus 21.0%, P < 0.001). Infliximab was the most frequently used drug (63.2%). In more than 71.8%, a clinical response of the underlying EIM to anti-TNF therapy was observed. In 92 patients (43.2%), anti-TNF treatments were started for the purpose of treating EIM rather than IBD. Response rates to anti-TNF were generally good and best for psoriasis, aphthous stomatitis, uveitis, and peripheral arthritis. In 11 patients, 14 EIM occurred under anti-TNF treatment. Conclusions: Anti-TNF was frequently used among patients with EIM. In more than 40%, anti-TNF treatments are started to treat EIM rather than IBD. Given the good response rates, anti-TNF seems to be a valuable option in the treatment of EIM, whereas appearance of EIM under anti-TNF does not seem to be a source of considerable concern.

[1]  L. French,et al.  Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort , 2015, Inflammatory bowel diseases.

[2]  G. Rogler,et al.  Extraintestinal Manifestations of Inflammatory Bowel Disease , 2015, Inflammatory bowel diseases.

[3]  G. Rogler,et al.  Biologics for extraintestinal manifestations of IBD. , 2014, Current drug targets.

[4]  G. Rogler,et al.  Induction or Exacerbation of Psoriasis in Patients with Crohn's Disease under Treatment with Anti-TNF Antibodies , 2014, Digestion.

[5]  F. García-Campos,et al.  Steroid-refractory ulcerative colitis and associated primary sclerosing cholangitis treated with infliximab. , 2013, World journal of gastroenterology.

[6]  J. E. Domínguez-Muñoz,et al.  Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease. , 2012, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[7]  W. Reinisch,et al.  Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: Results from CARE , 2012, Inflammatory bowel diseases.

[8]  G. Rogler,et al.  Frequency and Risk Factors for Extraintestinal Manifestations in the Swiss Inflammatory Bowel Disease Cohort , 2011, The American Journal of Gastroenterology.

[9]  P. Sarzi-Puttini,et al.  Combined therapeutic approach: inflammatory bowel diseases and peripheral or axial arthritis. , 2009, World journal of gastroenterology.

[10]  G. Fiorino,et al.  Review article: anti TNF‐α induced psoriasis in patients with inflammatory bowel disease , 2009, Alimentary pharmacology & therapeutics.

[11]  P. Munkholm,et al.  Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  D. Hommes,et al.  A Double-blind, Placebo-controlled, Randomized Study of Infliximab in Primary Sclerosing Cholangitis , 2008, Journal of clinical gastroenterology.

[13]  M. Regueiro,et al.  Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. , 2007, Inflammatory bowel diseases.

[14]  S. Christen-Zäch,et al.  Infliximab for the Treatment of Disseminated Pyoderma Gangrenosum Associated with Ulcerative Colitis , 2007, Dermatology.

[15]  B. Miller,et al.  Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. , 2006, Journal of the American Academy of Dermatology.

[16]  A. Forbes,et al.  Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial , 2005, Gut.

[17]  J. Mendoza,et al.  Manifestaciones extraintestinales en la enfermedad inflamatoria intestinal: diferencias entre la enfermedad de Crohn y la colitis ulcerosa , 2005 .

[18]  C. Bernstein,et al.  The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. , 2005, Gastroenterology.

[19]  J. McDonnell,et al.  Important cutaneous manifestations of inflammatory bowel disease , 2005, Postgraduate Medical Journal.

[20]  M. Yaron,et al.  The effect of infliximab on extraintestinal manifestations of Crohn’s disease , 2005, Rheumatology International.

[21]  R. Baldassano,et al.  Extraintestinal manifestations of inflammatory bowel disease. , 2005, Minerva gastroenterologica e dietologica.

[22]  F. Castiglione,et al.  Infliximab in the treatment of extra‐intestinal manifestations of Crohn's disease , 2005, Scandinavian journal of rheumatology.

[23]  A. Gottlieb,et al.  Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. , 2004, Journal of the American Academy of Dermatology.

[24]  A. del Rosso,et al.  Infliximab in spondyloarthropathy associated with Crohn’s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations , 2004, Annals of the rheumatic diseases.

[25]  A. Zinsmeister,et al.  Autoimmune Disorders and Extraintestinal Manifestations in First-degree Familial and Sporadic Inflammatory Bowel Disease: A Case–Control Study , 2004, Inflammatory bowel diseases.

[26]  M. Regueiro,et al.  Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease , 2003, American Journal of Gastroenterology.

[27]  S. Kugathasan,et al.  Dermatologic Manifestations of Crohn Disease in Children: Response to Infliximab , 2003, Journal of pediatric gastroenterology and nutrition.

[28]  G. Rogler,et al.  Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease , 2002, American Journal of Gastroenterology.

[29]  Nancy Xiaonan Yu,et al.  The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study , 2001, American Journal of Gastroenterology.

[30]  W. Hop,et al.  Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study , 2000, American Journal of Gastroenterology.

[31]  F. T. Veloso,et al.  Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. , 1996, Journal of clinical gastroenterology.

[32]  J. Lennard-jones,et al.  Pyoderma gangrenosum in inflammatory bowel disease , 1991, The British journal of surgery.

[33]  G. Hellers,et al.  Extracolonic diagnoses in ulcerative colitis: an epidemiological study. , 1990, The American journal of gastroenterology.

[34]  J. S. Taylor,et al.  Clinical course and evolution of erythema nodosum and pyoderma gangrenosum in chronic ulcerative colitis: a study of 42 patients. , 1985, The American journal of gastroenterology.

[35]  G. Watkinson,et al.  Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis , 1982, The British journal of dermatology.

[36]  H. Watts,et al.  National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. , 1979, Gastroenterology.

[37]  G. Van Assche,et al.  Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[38]  G. Fiorino,et al.  Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. , 2014, Autoimmunity reviews.

[39]  E. Szigethy,et al.  Inflammatory bowel disease. , 2011, Pediatric clinics of North America.

[40]  E. Rubio-Nazábal,et al.  [Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn's disease and ulcerative colitis]. , 2006, Medicina clinica.

[41]  J. Mendoza,et al.  [Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn's disease and ulcerative colitis]. , 2005, Medicina clinica.

[42]  K. Das.  Relationship of Extraintestinal Involvements in Inflammatory Bowel Disease (New Insights into Autoimmune Pathogenesis) , 2004, Digestive Diseases and Sciences.

[43]  W. Fries,et al.  Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab , 2002, American Journal of Gastroenterology.

[44]  G. Rogler,et al.  Extraintestinal Manifestations of In fl ammatory Bowel Disease , 2022 .